A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment

Ann Hematol. 2018 Oct;97(10):2009-2010. doi: 10.1007/s00277-018-3348-z. Epub 2018 May 1.

Authors

Yuriko Fujita¹, Tomonori Nakazato², Chisako Ito¹, Kyoko Masuda¹, Yuki Osada¹, Yoshinobu Aisa¹, Takehiko Mori³

Affiliations

¹ Department of Hematology, Yokohama Municipal Citizen's Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, 240-8555, Japan.
² Department of Hematology, Yokohama Municipal Citizen's Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, 240-8555, Japan. n-tomo@eurus.dti.ne.jp.
³ Division of Hematology, Keio University School of Medicine, Tokyo, Japan.

PMID: 29713749
DOI: 10.1007/s00277-018-3348-z

No abstract available

Keywords: Azacitidine; Factor V inhibitor; Myelodysplastic syndrome.

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Anemia, Refractory, with Excess of Blasts / complications*
Anemia, Refractory, with Excess of Blasts / drug therapy
Autoimmune Diseases / drug therapy
Autoimmune Diseases / etiology*
Autoimmune Diseases / immunology
Azacitidine / adverse effects
Azacitidine / therapeutic use*
Early Diagnosis
Factor V / immunology*
Factor V Deficiency / drug therapy
Factor V Deficiency / etiology*
Factor V Deficiency / immunology
Gingival Hemorrhage / etiology
Humans
Immunosuppressive Agents / therapeutic use
Male
Partial Thromboplastin Time
Prednisone / therapeutic use
Prothrombin Time

Substances

Immunosuppressive Agents
Factor V
Azacitidine
Prednisone